Translating TCR-Based Cell Therapies into the Clinic

•  Enabling technologies for allogeneic TCR-engineered Treg therapies for autoimmune disease
• Safety considerations and risk-mitigation approaches for an allogeneic TCR therapies for autoimmune disease
• Regulatory strategy and IND-enabling experience for autologous TCR-based cell therapy programs

Speakers:

Gene Uenishi

associate director

GentiBio